Facing the intertwined challenges of declining birth rates and an aging population, building a “family-friendly, precision-care” healthcare system has become a critical issue for national sustainability. Kaohsiung Medical University Chung-Ho Memorial Hospital (KMU Hospital), a cornerstone of southern Taiwan’s medical landscape and a key player in global healthcare integration, has signed a memorandum of understanding (MOU) with global biotech leader Merck. The partnership will focus on four core areas: international academic exchange, integrated clinical data generation, talent development, and patient-centered care, injecting concrete momentum into President Lai Ching-te’s “Healthy Taiwan Cultivation Plan.”

Through the integration and analysis of clinical data, the collaboration will advance personalized precision medicine, enhancing treatment outcomes and patient care quality. Beyond strengthening capabilities in clinical trials and medical data analysis, the partnership aims to attract international collaboration and investment, positioning southern Taiwan as a hub for clinical innovation in the Asia-Pacific region. In talent development, KMU Hospital and Merck will establish a professional exchange platform to facilitate international physician training and clinical observation in Taiwan, elevating the global influence of Taiwan’s medical education. This initiative will position KMU Hospital as a model hub for cultivating medical talent with cross-cultural clinical expertise and global competitiveness.